Is Keeping the Colon the Ultimate Marker of Success in Ulcerative Colitis?
No abstract is available. To read the body of this article, please view the Full Text online.
Conflicts of interest The authors disclose the following: Dr Nguyen has served on advisory boards for Schering-Plough, Canada, and Abbott Pharmaceuticals before the writing of this editorial. Dr Nguyen was not involved with the design or conduct of the ACT-1 or ACT-2 trials nor does he have any collaborative relationship with any of the investigators. There was no communication or input from any of the investigators or from any pharmaceutical company with regards to the contents of this editorial.
Dr Prather has served as a consultant for Proctor and Gamble. Dr Prather was not involved with the design or conduct of the ACT-1 or ACT-2 trials nor does she have any current or prior collaborative relationship with any of the investigators or the sponsor of the study. There was no communication or input from any of the investigators or from any pharmaceutical company with regards to the contents of this editorial.
PII: S0016-5085(09)01489-9
doi:10.1053/j.gastro.2009.08.024
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
-




Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
, 13 July 2009

